Intraoperative Glycaemia Following Paracetamol with and without Glucose: A Randomized-Controlled Trial

Ricardo Mota Pereira¹*, Fátima Gonçalves¹, João Costa²,³,⁴, Filomena Couto⁵, Carolina Sá¹, Isabel Neves¹, Lucindo Ormonde¹,⁴

¹Department of Anaesthesiology, Santa Maria University Hospital, Lisbon, Portugal; ²Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal; ³Evidence-Based Medicine Centre, Faculty of Medicine, University of Lisbon, Lisbon, Portugal; ⁴Instituto de Medicina Molecular (IMM), Faculty of Medicine, University of Lisbon, Lisbon, Portugal; ⁵Department of Gynaecology, Santa Maria University Hospital, Lisbon, Portugal.

Email: *ricardopereira@gmail.com

Received August 3rd, 2013; revised August 31st, 2013; accepted September 6th, 2013

ABSTRACT

Background: Hyperglycaemia is conversely a risk factor for perioperative complications. We are currently using a generic 3.3 g glucose containing formula of intravenous 1000 mg paracetamol for perioperative analgesia. Our main goal was to compare the trends of glycaemic values after administration of a generic 3.3 g glucose containing formula with a non-glucose containing branded formula of intravenous 1000 mg paracetamol. Methods: A exploratory proof-of-concept randomized clinical trial was conducted with 150 patients scheduled for elective gynaecologic. Patients were randomly assigned into three groups: control group (saline); active-control group: intraoperative administration of a branded non-glucose containing 1000 mg paracetamol formula; experimental group: intraoperative administration of a generic 3.3 g glucose containing 1000 mg paracetamol formula. The primary outcome was mean change from baseline in glycaemia. In case significant differences were found, the following secondary outcomes were explored: the proportion of patients with high glycaemia values (>150 mg/dL) and the proportion of patients with negative glycaemic variation. Results: Mean glycaemia change was higher after generic 3.3 g glucose containing paracetamol formula both in comparison to placebo (16.3 mg/dL [95% CI: 6.1 to 26.6]) and active-control (19.1 mg/dL [8.2 to 30.0] groups. Similar results were found in the intention-to-treat analysis. In only the experimental group, patients had high glycaemic values (11.3%). Conclusions: This study showed that in non-diabetic, under non-cardiac surgery, administration of a generic glucose-containing formula of intravenous 1000 mg paracetamol was associated with poorer glycaemic control. These results raise the question of a possible increased risk among these patients. Further studies using diabetic patients are recommended.

Keywords: Paracetamol; Hyperglycaemia; Gynecologic Surgical Procedures; Randomized Controlled Trial

1. Introduction

It has been demonstrated that inadequate glycaemic control in surgical patients increases perioperative morbidity and mortality [1]. While most studies focus on neurosurgical [2], cardiac [3-5] and critical care patients [6], and therefore further investigation is required, some of the outcome key findings are most probably applicable to general surgical patients [5].

Acute hyperglycaemia is associated with several deleterious effects such as suppressed immune function, increased systemic vascular resistance, dehydration, electrolyte and acid-base imbalance and central nervous system dysfunction [7]. Although patients with diabetes mellitus (DM) are at higher risk for perioperative complications [8], the occurrence of intraoperative acute hyperglycaemia in non-DM patients is also considered [9, 10] to be a strong and independent predictor of poorer outcome (sepsis, pneumonia, surgical wound infection). Furthermore, individuals with previous unknown hyperglycaemia are at even higher risk than those with pre-diagnosed DM [2].

Recent studies found that 21% to 34% of patients who underwent surgery had uncontrolled blood glucose level (Blood Glycaemia (BG) > 150 mg/dl), particularly in the immediate postoperative period (< 72 hours) [11]. Many of these patients may miss a DM diagnosis as only two
thirds of those have a pre-established DM diagnosis [12].

Paracetamol (acetaminophen) is one of the safest and more cost-effective [13] non-opioid analgesic when administered in analgesic doses. Paracetamol is considered an atypical nonsteroidal anti-inflammatory drug (NSAID) [14], given the nonspecific and weak inhibition of COX-3 [15], with central and peripheral effects.

In our hospital, it is currently in use a 3 g glucose containing formula of intravenous 1000 mg paracetamol for perioperative analgesia. To evaluate what is the impact of this glucose containing paracetamol formula in the intraoperative glycaemic control among non-diabetic general surgical patients, we conducted an exploratory proof-of-concept randomized clinical trial.

2. Methods

All patients provided their written informed consent for participating in this study, which was approved by the Ethics Committee of our Hospital (Santa Maria University Hospital, Lisbon). This was an academic trial without any direct or indirect funding.

2.1. Study Population

This study was conducted in the gynaecologic surgery department of Santa Maria University Hospital (Lisbon, Portugal). Non-diabetic female patients scheduled for elective gynaecologic procedure were consecutively recruited. Inclusion criteria were: 1) written informed consent; 2) age between 18 and 80 years-old; 3) body mass index (BMI) < 30 Kg/m²; 4) fasting glycaemic values > 60 mg/dL and <126 mg/dL; 5) American Society of Anesthesiology (ASA) classification ≤ 2; and 6) 8-hour fasting period. Patients with a diagnosis of DM or glucose impairment were excluded.

2.2. Study Design

Patients were randomly assigned to one of three groups: 1) Placebo-control group (saline); 2) Paracetamol 1000 mg in a non-glucose containing formula (active-control group), and; 3) Paracetamol 1000 mg in a 3 g glucose containing formula (experimental group). All interventions were delivered in the last third of the surgical procedure (15 minutes infusion).

Random sequence generation was independently done by the principal investigator (RMP) that did not participate in the patients’ recruitment or evaluation. Opaque sealed envelopes in a closed box were used to retain the random codes and successively replaced until 150 consecutive patients were obtained. Hence, each new patient had an equal chance of being allocated to one of the three treatment groups. Allocation concealment was achieved by making patients and assessment investigator (FC) blind to treatment assignment. The investigators (FG, FC) who administered the treatment were the only subjects that were not blind to treatment assignment, however they didn’t participated further in the study.

Primary outcome was defined as the mean change from baseline in blood glucose. If significant differences were found between groups, the following secondary outcomes were investigated: proportion of patients with high glycaemia values (>150 mg/dL) in the second measurement and proportion of patients with negative variation in glycaemia between the two measurements. The same investigator (FC) assessed all patients and performed all measurements. Fingerprick capillary glucose was determined at the beginning of the surgery (baseline glycaemia) and 10 minutes after treatment infusion ending (post-interventional glycaemia), using the Precision Xceed Pro point-of-care glucometer (Abbott), which was calibrated daily. All test-trips used were taken from the same lot. For the capillary glucose measurement, the second finger from the opposite arm in which the drug was administrated, was chosen. In none of the glycemiac measurements was found an invalid value, making unnecessary a second attempt.

2.3. Anaesthesia Protocol

After an 8-hour preoperative fasting, all patients were pre-medicated with midazolam 0.05 mg/kg. General anaesthesia was induced with single doses of fentanyl (5 ug/kg) and propofol (2 mg/kg) given slowly as bolus injections. Traqueal intubation was facilitated with rocuronium (0.4 mg/kg) and anaesthesia maintained with sevoflurane vaporized in air and oxygen mixture (FiO₂ 0.4) titrated to achieve stable hemodynamics.

2.4. Statistical Analysis and Data Synthesis

This was an exploratory trial and we planned to enrol 40 patients per treatment group. Assuming that the response within each subject group is normally distributed with standard deviation (SD) of 20 mg/dL, this sample size will allow detecting a true difference in the mean response of treatment groups (experimental, placebo-control and active-control) of 15 mg/dL with a probability (power) of 82% (analysis of variance with Bonferroni correction). We considered that such difference is of potential clinical significance. The Type I error probability associated with this test of the null hypothesis that the population means of the experimental and controls groups were equal was 0.05.

The mean change from baseline in glycaemia values between groups (primary outcome: dependent variable) was compared using a full factorial generalized linear model (GLM) with treatment group as main effect and including terms for age, fasting period (Nulla per os: NTO), surgery duration and baseline glycaemia. Interac-
Intraoperative Glycaemia Following Paracetamol with and without Glucose: A Randomized-Controlled Trial

150 consecutive patients were randomized between January and May 2011. Seventeen patients were excluded from the per-protocol analysis because of missing data from the second glycaemia evaluation (n = 12) and deviation of study protocol (the anaesthesiologist did not administer the treatment according to the protocol; n = 5). As a result, a total of 133 patients were included in the per-protocol analysis (primary analysis) and 145 patients in the ITT analysis. Figure 1 shows the study’s flow diagram. The main characteristics of the patients are shown in Table 1.

As a result of the chosen randomization methodology, different groups sizes were obtained (49, 42 and 59 patients, for placebo-control, active-control and experimental groups, respectively) since each new patient had the same probability chance to be included in the different groups.

Figure 1. Study flow diagram. Mismatch collecting data due to second glycaemia measurements (lacks of post-interventional glycaemia). Therapeutic error due to intraoperative administration of saline enriched with dextrose.
No significant interactions existed between treatment, surgery time, NPO and baseline glycaemia. Placebo control group patients were younger than in the other groups (p = 0.014). Table 2 shows the main results for the per-protocol and ITT analysis of the primary outcome (mean change from baseline in blood glucose), as well as the results of the exploratory secondary outcomes. Post-hoc analysis for the primary outcome showed significant differences between the experimental group and both placebo and active-control groups (p ≤ 0.001 for both per-protocol and ITT data), without significant differences between the placebo and the active-control group. For the per-protocol population, the mean difference between the experimental and the placebo and active-control groups was 16.3 mg/dL (95% CI: 6.1 to 26.6) and 19.1 mg/dL (95% CI: 8.2 to 30.0), respectively.

For the ITT population, these differences were 15.0 mg/dL (95% CI: 5.2 to 24.7) and 18.4 mg/dL (95% CI: 7.9 to 28.8), respectively.

In only the experimental group, patients (11.3%) had high glycaemia values (Figure 2). All glycaemic measurements were above threshold for hypoglycaemia (minimum glucose value was 65 mg/dL, 74 mg/dL and 66 mg/dL for placebo-control, active-control and experimental groups, respectively).

### 4. Discussion

The most relevant findings of our study are: 1) intravenous paracetamol formulation containing glucose is associated with a mean increase of glycaemia in female non-diabetic patients submitted to elective gynaecological surgery; Similar results were found considered both per-protocol and ITT analysis, which strengths this conclusion; 2) intravenous paracetamol formulation containing glucose is associated with a higher proportion of patients showing poor glycaemic control. In fact, only patients randomised to the experimental group had absolute glucose blood values above the so-called “hyperglycaemic barrier” (>150 - 180 mg/dL).

As previously described, high glycaemic values might increase the risk of occurrence of adverse effects and poor outcomes after surgery. The clinical association between hyperglycaemia and adverse clinical outcomes was first reported in 1985 when Longstreth and Inui [4] demonstrated a poorer neurologic recovery following out-of-hospital cardiac arrest associated with hyperglycaemia. Several mechanisms promote hyperglycaemia as a response to the metabolic stress during surgery, namely through the production and release of the counterregulatory hormones (glucagon, epinephrine and cortisol) [7], peripheral insulin resistance throughout glucocorticoid therapy [2] and glucose-stimulated insulin depression by inhalatory anesthetic agents. Although patients with DM have a higher incidence of perioperative complications [16,17], development of acute hyperglycaemia peroperatively per se (i.e. even in those with previously normal glucose tolerance) is also recognized as a predictor of adverse outcome. [7,18]

The goal of optimal glycaemic values has been the subject of several studies. [19-21] Nevertheless, the glycaemic values considered as optimal for medical and surgical patients have been controversial, both for the intra- or perioperative periods and for critical or non-critical patients. Van der Bergh et al. reported the first major trial of intensive insulin therapy (ITT) in an adult critical care unit. By targeting blood glucose < 110 mg/dL, they reported a 32 % (95% CI: 2% - 55%) risk reduction in mortality, particularly from multiple organ failure and sepsis. [22] Unfortunately, several subsequent multi-institutional studies have failed to replicate these results. The NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation-Survival Using Glucose Algorithm Regulation) reported an increase risk of death at 90 days (Odds Ratio 1.14; 95% CI: 1.02 - 1.28) with ITT strategy to achieve 81 - 108 mg/dL compared with a more relaxed target (<180 mg/dL). According to the authors, this mortality increase was related with the higher risk of hypoglycaemia episodes. [23]

Although there’s controversy between the benefits of
tight blood glucose control (<110 mg/dl) versus the standard blood glucose management (<200 mg), there is some data [24] suggesting that glycaemic values above 140 mg/dl are associated with post-operative complications and poorer outcome. In fact, randomized controlled trials in medical [23], cardiac [25-27] and neurosurgical [28] populations have found reduced rates of bacteremia, duration of antibiotic usage, infections rates [29], and incidence of recurrent infections in patients with tight glycaemic control (<150 mg/dl) [1]. Margarita Ramos et al. further showed that every 40 mg/dL increase in post-operative glucose above those values led to a 30% increased risk of postoperative infections (pneumonia, wound infections, urinary tract infections and sepsis) in the first 30 days after surgery [30].

Most of the research on glucose control has been conducted in the critical care setting and the results obtained, being later generalized to the non-critical and non-cardiac surgery patients [1,31]. In 2010, the Society for Ambulatory Anaesthesia (SAMBA) [32] published guidelines for perioperative management in diabetic patients undergoing ambulatory surgery. According to this guideline, in patients with well-controlled diabetes the intra-operative blood glucose levels should be maintained below 180 mg/dl. Guidelines for non-critical and non-DM patients are still lacking. Our results are a first contribution for an evidence-based discussion on this matter.

In addition, perioperative glycaemic control also depends on hypoglycaemia prevention, namely due to potential neurological injury. [33,34] A blood glucose level below 70 mg/dl is generally considered an alert value for hypoglycaemia. [35] This end point value allows time for prevention of symptomatic hypoglycaemia, which usually occurs at blood glucose levels of 45 to 55 mg/dl. [32] During our study, no patients showed hypoglycaemia.

It is predictable that any anaesthetic technique that modifies the intra-operatively neuroendocrine stress response could also modulate the subsequent metabolic sequelae and mitigate perioperative hyperglycaemia. [7] It is well known the benefit effect of blocking the sympathetic neuroendocrine response through the spinal and epidural anaesthetic techniques on the preventive strategy of suppressing the hyperglycaemic stimulus [36].

![Figure 2. Baseline and post-interventional glycaemia for individual patients, according to treatment group. Values are expressed in mg/dL.](image)
ferently, propofol and opioids do not have a major effect on glucose metabolism. [2] In this study, all patients were submitted to surgery under balanced general anaesthesia and with the same anaesthetic protocol, according to patients’ weight. Therefore, our study is not likely biased due to confounding anaesthetic variables.

A variety of measurement techniques are currently in use. Arterial samples are considered more accurate [37]. It is known that capillary testing should be avoided in patients with haematocrit levels <25% or >60%, in shock, with severe dehydration and when vasoactive agents such as norepinephrine are given [38-40]. However, for most surgical patients, phlebotomy or arterial access is not routine [41]. In hemodynamically stable patients the capillary glucose meter correlates well with laboratory reference values [7] and is strongly correlated with arterial samples [41]. Also, the laboratory plasma values generally provide little additional information for non-ICU patients and typically lower the mean glucose [42]. In this study, all patients were hemodynamically stable and non-critically ill, submitted to minor/moderate gynaecologic procedures. Therefore, we think that the glycaemia measurement technique used in our study does not represent a major limitation. Furthermore, to minimize bias, the same investigator using the same capillary glucose meter and technique, performed all measurements.

In our hospital, paracetamol is included in the analgesic strategy for all patients (medical and surgical). Several peripheral and central mechanisms of action have been suggested to explain the paracetamol analgesic properties including selective inhibition of cyclooxygenase activity in the CNS, spinal interaction with 5-HT3 receptors [14], inhibition of neurons excited by substance P and activation of suprasegmental descending inhibitory pathways [15]. Due to the analgesic properties, paracetamol plays a key role in suppressing the surgery-induced pain adrenergic stimulation, and this suppression could, in theory, blunt the adrenergic hyperglycaemic response. In our opinion, this is the most plausible explanation for the findings in the paracetamol (without glucose) group, which had the lowest increase in glycaemia.

Finally, as with most studies, this also presented some limitations. First, this was an exploratory trial, which aimed to address the question if paracetamol with glucose is associated with an increased risk of poorer glycaemic control. We have not evaluated the clinical consequences of this poorer glycaemic control. Second, sample size was relatively small and we included only female patients undergoing minor to moderate gynaecologic procedures. This precludes the external validity of the findings to other non-diabetic populations and gender. Third, female patients underwent different types of surgeries. We have not performed post-hoc subgroup analysis because of low power. The possibility exists that the results could also differ according to the type of surgery. Fourth, the paracetamol brand used in the experimental (Paracetamol-APS®) and active-control (Perfalgan®) groups were different. Although these are thought to be equivalent, we cannot rule out bias emerging from this difference.

5. Conclusion

In conclusion, our results strongly suggest that administration of a glucose containing formula of paracetamol may increase the risk of perioperative hyperglycemia in non-diabetic patients submitted to non-cardiac surgery. However, this was an exploratory “proof-of-concept” trial and, although the results were robust, conclusions and implications for practice should be thought with caution. Future clinical research should address the postoperative outcomes and potential consequences of this poorer glycaemic control.

6. Acknowledgements

Specific author contributions: RMP contributed to the concept and design, data analysis, and interpretation of the data; wrote the first draft of the manuscript; critically revised the manuscript; and gave final approval of the submitted manuscript. FG contributed to the concept, design, and data acquisition; critically revised the manuscript; and gave final approval of the submitted manuscript. JC contributed to data analysis, and interpretation of the data; critically revised the manuscript; and gave final approval of the submitted manuscript. IN made contribution in the concept and design; and gave final approval of the submitted manuscript. LO gave final approval of the submitted manuscript.

Financial support and sponsorship: This was an academic project without any direct or indirect funding.

Conflicts of interest: The authors do not have any potential conflict of interest to declare.

Acknowledgement: Cochrane Coordinating Centre in Portugal.

REFERENCES


